Blueprint Medicines (NASDAQ: BPMC) reported Q3 EPS of ($1.93), versus $1.66 reported last year. Revenue for the quarter came in at $9.14 million, versus $1.1 million reported last year.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.